October 8, 2024
Advancing Global Progress in PIDs: Insights from IPOPI’s 3rd Global Stakeholders Summit
The third edition of the Global Stakeholders Summit was held on July 1-2, bringing together experts and advocates to continue our collaborative efforts in exploring new horizons and innovations for global progress in PIDs.
The objective of the IPOPI Global PID Stakeholder’s Summits is to facilitate a forward-thinking meeting and brainstorming discussion among stakeholders in the PID community. This edition aimed to identify the future priorities, unmet needs, hurdles, and opportunities for PID by engaging participants in active and provocative discussions. The summit consisted of three sessions, each focusing on distinct aspects of PID care, namely breakthroughs in genomic medicine, the integration of AI in healthcare, and strategies for ensuring long-term access to treatments. These subjects were addressed through presentations and interactive sessions covering themes such as the potential for DNA editing to cure genetic diseases, advancements in gene and T-cell therapies, the role of AI in improving diagnostics and personalised care and overcoming regulatory challenges to secure safe and sufficient treatment options for future PID patients.
The 2024 IPOPI Global PID Stakeholder’s Summit provided a platform for in-depth discussions, collaboration, and the identification of critical priorities in the PID field. The outcomes of this summit have the potential to guide future actions, innovative therapy development, and regulatory framework discussions, striving to optimize PID care.
Following the publication of the outcomes of the previous IPOPI Global PID Stakeholder’s Summits in Frontiers in Immunology (Tadros et al. 2023; Van Coillie et al. 2024), the proceedings of this 3rd summit are set to be published as well. With this, we hope to ensure that the valuable insights and discussions from the event reach a wider audience.
We look forward to our 2025 summit as we continue to drive healthcare innovation together.
With thanks to our Global Stakeholders Summit sponsors for their support: CSL Behring, Grifols, Kedrion and Takeda
